Search results
Showing 931 to 945 of 7707 results
Evidence-based recommendations on tenecteplase (Metalyse) for treating acute ischaemic stroke in adults.
Risankizumab for treating moderately to severely active ulcerative colitis (TA998)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.
Evidence-based recommendations on removing wisdom teeth in adults.
Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)
Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)
Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults.
Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.
After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA859
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy because no evidence submission was received from Merck Sharp & Dohme. We will review this decision if the company decides to make a submission
Show all sections
Sections for TA570
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)
Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.